West Health Investment Fund invests in GlySens and RxAnte

Startups demonstrate innovative technologies to lower the cost of health care in the treatment of diabetes and medication adherence

SAN DIEGO, CA. – Sept. 12, 2012 – The West Health Investment Fund, West Health’s fund focused on lowering health care costs, has announced it participated in the recent venture financings of GlySens, Inc. and RxAnte, Inc., two startup technology companies with innovative technologies that could lower the cost of health care. Financial terms of the investments were not disclosed.

“Through targeted external investments in companies focused in advancing cost-effective and cost-saving models of care, West Health can impact the cost of health care in the country,” said Nicholas J. Valeriani, chief executive of West Health.  “These two innovative companies highlight the kinds of new approaches to diabetes treatment and medication adherence that have great potential to disrupt the current delivery model and lower the cost of health care.”

West Health can impact the cost of health care in the country,” said Nicholas J. Valeriani, chief executive of West Health. “These two innovative companies highlight the kinds of new approaches to diabetes treatment and medication adherence that have great potential to disrupt the current delivery model and lower the cost of health care.” – See more at: http://www.westhealth.org/news/west-health-investment-fund-invests-glysens-and-rxante#sthash.nagJpz9h.dpuf
West Health can impact the cost of health care in the country,” said Nicholas J. Valeriani, chief executive of West Health. “These two innovative companies highlight the kinds of new approaches to diabetes treatment and medication adherence that have great potential to disrupt the current delivery model and lower the cost of health care.” – See more at: http://www.westhealth.org/news/west-health-investment-fund-invests-glysens-and-rxante#sthash.nagJpz9h.dpuf

Read more…